Questions About Cancer? 1-800-4-CANCER

Neuroblastoma Treatment (PDQ®)

Health Professional Version
Last Modified: 01/14/2014

Changes to this Summary (01/14/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment of High-Risk Neuroblastoma

Revised text about the Children's Oncology Group (COG) ANBL12P1 trial to state that the International Society of Paediatric Oncology European Neuroblastoma Group published a comparison of the conditioning regimen busulfan/melphalan (BuMel) versus carboplatin/etoposide/melphalan, and BuMel showed better survival outcomes. Also added text to state that the outcome of this trial will influence the choice of preparative regimens used in upcoming COG high-risk neuroblastoma trials.

Added text about the COG-ANBL09P1 trial as a treatment option under clinical evaluation.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.